-
公开(公告)号：US20210347914A1
公开(公告)日：2021-11-11
申请号：US17379739
申请日：2021-07-19
Applicant: Banyan Biomarkers, Inc.
Inventor： Michael CATANIA , Ronald L. HAYES
Abstract: The invention provides anti-UCH-L1 antibodies and anti-GFAP antibodies and their use in in vitro detection of UCH-L1 and GFAP, respectively, in a sample from an individual, such as an individual known or suspected of having a brain injury or damage, for example, neurological damage such as mild traumatic brain injury. Also provided are methods, systems and kits for diagnosing brain injury or damage, such as neurological damage, in an individual with the aforementioned antibodies as well as compositions comprising the anti-UCH-L1 antibodies and anti-GFAP antibodies.
-
2.发明申请公开(公告)号：US20200165355A1
公开(公告)日：2020-05-28
申请号：US16345562
申请日：2017-10-27
Applicant: BANYAN BIOMARKERS, INC.
Inventor： Michael CATANIA , Ronald L. HAYES
Abstract: The invention provides anti-UCH-L1 antibodies and anti-GFAP antibodies and their use in vitro detection of UCH-L1 and GFAP, respectively, in a sample from an individual, such as an individual known or suspected of having a brain injury or damage, for example, neurological damage such as mild traumatic brain injury. Also provided are methods, systems and kits for diagnosing brain injury or damage, such as neurological damage, in an individual with the aforementioned antibodies as well as compositions comprising the anti-UCH-L1 antibodies and anti-GFAP antibodies.
-
公开(公告)号：US20170307640A1
公开(公告)日：2017-10-26
申请号：US15630734
申请日：2017-06-22
Applicant: BANYAN BIOMARKERS, INC.
Inventor： Firas KOBAISSY , Joy GUINGAB , Kevin Ka-Wang WANG , Ronald L. HAYES
IPC: G01N33/68
CPC classification number: G01N33/6896
Abstract: The present invention identifies biomarkers that are diagnostic of neural injury, neuronal disorder or neurotoxicity and is related to the discovery that proteases are selectively activated in subjects suffering from nervous system damage as compared to healthy subjects. Breakdown products reflecting protease activation are produced and detection of these different biomarkers of the invention is also diagnostic of the degree of severity and type of nerve damage in a subject.
-
公开(公告)号：US20190064188A1
公开(公告)日：2019-02-28
申请号：US16052512
申请日：2018-08-01
Applicant: Banyan Biomarkers, Inc.
Inventor： Kevin Ka-Wang WANG , Zhiqun ZHANG , Ming-Cheng LIU , Ronald L. HAYES
IPC: G01N33/68 , C07K16/18 , G01N33/53 , G01N33/564 , C12Q1/6883
Abstract: Processes and materials are provided for the detection, diagnosis, or determination of the severity of a neurological injury or condition, including traumatic brain injury, multiple-organ injury, stroke, Alzeimer's disease, Parkinson disease and Chronic Traumatic Encephalopathy (CTE). The processes and materials include biomarkers detected or measured in a biological sample such as whole blood, serum, plasma, or CSF. Such biomarkers include Tau and GFAP proteins, their proteolytic breakdown products, brain specific or enriched micro-RNA, and brain specific or enriched protein directed autoantibodies. The processes and materials are operable to detect the presence of absence of acute, subacute or chronic brain injuries and predict outcome for the brain injury.
-
公开(公告)号：US20180031577A1
公开(公告)日：2018-02-01
申请号：US15709368
申请日：2017-09-19
Applicant: BANYAN BIOMARKERS, INC.
Inventor： Kevin Ka-wang WANG , Ronald L. HAYES , Uwe R. MUELLER , Zhiqun ZHANG
IPC: G01N33/68
CPC classification number: G01N33/6896 , G01N2800/28 , G01N2800/2871 , G01N2800/60
Abstract: The subject invention provides a robust, quantitative, and reproducible process and assay for diagnosis of a neurological condition in a subject. The invention provides measurement of two or more biomarkers in a biological fluid such as CSF or serum resulting in a synergistic mechanism for determining the extent of neurological damage in a subject with an abnormal neurological condition and for discerning subtypes thereof or tissue types subjected to damage.
-
Patent Agency Ranking
公开(公告)号：US20170242041A1
公开(公告)日：2017-08-24
申请号：US15391755
申请日：2016-12-27
Applicant: BANYAN BIOMARKERS, INC.
Inventor： Kevin Ka-Wang WANG , Zhiqun ZHANG , Ming-Cheng LIU , Ronald L. HAYES , Jitendra Ramanlal DAVE
IPC: G01N33/68 , G01N33/53 , C07K16/18 , G01N33/564
CPC classification number: G01N33/6896 , C07K16/18 , C12Q1/6883 , C12Q2600/178 , G01N33/5308 , G01N33/564 , G01N2800/28
Abstract: Processes and materials are provided for the detection, diagnosis, or determination of the severity of a neurological injury or condition, including traumatic brain injury, multiple-organ injury, stroke, Alzeimer's disease, Parkinson disease and Chronic Traumatic Encephalopathy (CTE). The processes and materials include biomarkers detected or measured in a biological sample such as whole blood, serum, plasma, or CSF. Such biomarkers include Tau and GFAP proteins, their proteolytic breakdown products, brain specific or enriched micro-RNA, and brain specific or enriched protein directed autoantibodies. The processes and materials are operable to detect the presence of absence of acute, subacute or chronic brain injuries and predict outcome for the brain injury.
-
公开(公告)号：US20240368308A1
公开(公告)日：2024-11-07
申请号：US18781407
申请日：2024-07-23
Applicant: BANYAN BIOMARKERS, INC.
Inventor： Michael CATANIA , Ronald L. HAYES
Abstract: Anti-UCH-L1 antibodies and anti-GFAP antibodies and their use in in vitro detection of UCH-L1 and GFAP, respectively, in a sample from an individual, such as an individual known or suspected of having a brain injury or damage, for example, neurological damage such as mild traumatic brain injury. Also provided are methods, systems and kits for diagnosing brain injury or damage, such as neurological damage, in an individual with the aforementioned antibodies as well as compositions including the anti-UCH-L1 antibodies and anti-GFAP antibodies.
-
公开(公告)号：US20240264177A1
公开(公告)日：2024-08-08
申请号：US18637770
申请日：2024-04-17
Applicant: BANYAN BIOMARKERS, INC.
Inventor： Kevin Ka-Wang WANG , Ronald L. HAYES , Uwe R. MUELLER , Zhiqun ZHANG
IPC: G01N33/68 , A61B5/00 , G01N33/577
CPC classification number: G01N33/6896 , A61B5/4064 , G01N33/577 , G01N2800/28 , G01N2800/2871 , G01N2800/52 , G01N2800/56 , G01N2800/60
Abstract: A robust, quantitative, and reproducible process and assay for diagnosis of a neurological condition in a subject. The method includes measurement of two or more biomarkers in a biological fluid such as CSF or serum resulting in a synergistic mechanism for determining the extent of neurological damage in a subject with an abnormal neurological condition and for discerning subtypes thereof or tissue types subjected to damage.
-
公开(公告)号：US20210011028A1
公开(公告)日：2021-01-14
申请号：US16890943
申请日：2020-06-02
Applicant: Banyan Biomarkers, Inc.
Inventor： Kevin Ka-Wang WANG , Ronald L. HAYES , Uwe R. MUELLER , Zhiqun ZHANG
IPC: G01N33/68
Abstract: The subject invention provides a robust, quantitative, and reproducible process and assay for diagnosis of a neurological condition in a subject. The invention provides measurement of two or more biomarkers in a biological fluid such as CSF or serum resulting in a synergistic mechanism for determining the extent of neurological damage in a subject with an abnormal neurological condition and for discerning subtypes thereof or tissue types subjected to damage.
-
公开(公告)号：US20170242036A1
公开(公告)日：2017-08-24
申请号：US15441223
申请日：2017-02-23
Applicant: BANYAN BIOMARKERS, INC. , THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
Inventor： Harvey POLLARD , Lei ZHANG , Ofer EIDELMAN , Robert J. URSANO , He LI , Tung-Pi SU , Kevin Ka-Wang WANG , Ronald L. HAYES
IPC: G01N33/68 , G01N33/543 , C12Q1/68
CPC classification number: G01N33/6893 , C12Q1/6883 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , G01N33/5438 , G01N2333/4703 , G01N2333/4706 , G01N2333/4727 , G01N2333/52 , G01N2333/9015 , G01N2800/28 , G01N2800/30 , G01N2800/301 , G01N2800/52 , G01N2800/60
Abstract: Life-threatening traumas such as terrorist attacks, war, disasters, mental or physical assault, severe accidents and violence frequently provoke emotional and behavioral disturbances known as post-traumatic stress disorder (PTSD) and suicide related thereto. Accurate diagnosis and treatment planning for PTSD and suicide remain difficult. The discovery of specific markers creates new opportunities for more accurate clinical assessments identifying groups that may experience better outcomes when exposed to an intervention. The present invention provides a process of detection of P-11, UBE3A, STY1, EMAP-II, SIP1, ORC5L, DCX, SCYE protein in a biological sample of a subject suspected of suffering from PTSD and/or having suicidal tendencies, and provides additional PTSD markers which are specific to gender.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.013 seconds)
